Revenue
$1.22B
Fiscal year ended 2026-06-30Operating income
$425.57M
Fiscal year ended 2026-06-30Free cash flow
$322.52M
Fiscal year ended 2026-06-30IDEXX LABORATORIES INC /DE (IDXX) reported revenue of $1.22B and net income of $338.41M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from IDEXX LABORATORIES INC /DE’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.14B | $1.09B | $1.11B | $1.11B | $998.43M | $954.29M | $975.54M | $1.00B | $964.10M |
| Cost of revenue | $437.50M | $418.08M | $432.46M | $421.88M | $414.72M | $375.05M | $383.63M | $379.50M | $384.42M | $371.02M |
| Gross profit | $779.09M | $722.74M | $658.11M | $683.35M | $694.73M | $623.38M | $570.66M | $596.04M | $619.16M | $593.07M |
| Operating income | $425.57M | $362.59M | $315.60M | $354.85M | $373.05M | $316.53M | $261.69M | $303.89M | $263.80M | $298.96M |
| Net income | $338.41M | $278.45M | $248.19M | $274.61M | $293.99M | $242.68M | $216.15M | $232.84M | $203.30M | $235.58M |
| Research & development | $65.43M | $65.79M | $66.83M | $63.42M | $61.90M | $59.06M | $57.73M | $53.98M | $55.45M | $52.64M |
| Weighted-average diluted shares | shares 79.31M | shares 80.16M | Unavailable | shares 80.68M | shares 80.99M | shares 81.92M | Unavailable | shares 83.06M | shares 83.39M | shares 83.96M |
| Pretax income | $417.22M | $355.44M | $306.98M | $344.77M | $362.35M | $310.08M | $256.39M | $298.91M | $259.06M | $295.48M |
| Income tax expense | $78.81M | $77.00M | $58.79M | $70.16M | $68.36M | $67.41M | $40.24M | $66.07M | $55.76M | $59.90M |
| Diluted EPS | $4.27 | $3.47 | Unavailable | $3.40 | $3.63 | $2.96 | Unavailable | $2.80 | $2.44 | $2.81 |
| Selling, general & administrative | $288.09M | $294.36M | $275.68M | $265.09M | $259.79M | $247.78M | $251.24M | $238.17M | $299.91M | $241.48M |
| General & administrative | $116.82M | $119.12M | $108.62M | $105.94M | $98.68M | $91.56M | $101.14M | $91.89M | $157.24M | $92.02M |
| Selling & marketing | $171.28M | $175.25M | $167.06M | $159.16M | $161.11M | $156.22M | $150.11M | $146.28M | $142.66M | $149.45M |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $196.93M | $200.53M | $180.07M | $208.17M | $164.59M | $163.97M | $288.27M | $308.64M | $401.59M | $397.43M |
| Total assets | $3.44B | $3.39B | $3.35B | $3.39B | $3.33B | $3.21B | $3.29B | $3.35B | $3.41B | $3.35B |
| Current assets | $1.51B | $1.45B | $1.41B | $1.48B | $1.36B | $1.32B | $1.40B | $1.43B | $1.53B | $1.50B |
| Total liabilities | $1.83B | $1.83B | $1.75B | $1.83B | $1.87B | $1.77B | $1.70B | $1.73B | $1.83B | $1.78B |
| Current liabilities | $1.29B | $1.30B | $1.15B | $1.25B | $1.22B | $1.14B | $1.07B | $1.01B | $1.12B | $956.90M |
| Total equity incl. NCI | $1.61B | $1.56B | $1.61B | $1.56B | $1.46B | $1.45B | $1.60B | $1.62B | $1.58B | $1.57B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $391.58M | $382.40M | $377.76M | $391.56M | $392.58M | $395.99M | $381.88M | $389.80M | $379.96M | $390.60M |
| Accounts receivable | $627.08M | $603.54M | $552.38M | $566.88M | $560.56M | $527.46M | $473.58M | $511.25M | $533.61M | $507.21M |
| Goodwill | $410.95M | $412.10M | $414.00M | $413.65M | $414.49M | $407.49M | $405.10M | $412.07M | $408.02M | $408.67M |
| Long-term debt | $299.86M | $299.85M | $374.84M | $374.82M | $449.81M | $449.80M | $449.79M | $524.76M | $524.74M | $620.78M |
| Accounts payable | $129.10M | $129.97M | $110.41M | $122.26M | $116.58M | $120.10M | $114.21M | $110.60M | $117.47M | $117.46M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $347.16M | $266.25M | $355.76M | $402.34M | $185.74M | $237.96M | $262.02M | $220.08M | $248.31M | $198.58M |
| Capital expenditures | $24.65M | $31.98M | $29.43M | $31.11M | $34.10M | $30.03M | $29.26M | $28.09M | $33.30M | $30.27M |
| Investing cash flow | -$25.50M | -$33.54M | -$28.13M | -$44.87M | -$33.63M | -$29.61M | -$39.84M | -$27.37M | -$32.91M | -$106.94M |
| Financing cash flow | -$325.19M | -$211.43M | -$355.70M | -$313.31M | -$165.63M | -$330.32M | -$232.78M | -$290.98M | -$210.24M | -$144.07M |
| Net change in cash | -$3.60M | $20.46M | -$28.10M | $43.57M | $624.00K | -$124.30M | -$20.37M | -$92.95M | $4.16M | -$56.50M |
| Stock-based compensation | $16.09M | $16.34M | $16.11M | $14.43M | $14.85M | $14.62M | $14.26M | $15.92M | $15.72M | $14.40M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $346.80M | $351.04M | $237.77M | $240.20M | $338.10M | $400.89M | $245.99M | $220.76M | $215.52M | $154.76M |
| Depreciation & amortization | $41.05M | $37.68M | $38.72M | $36.63M | $35.77M | $34.06M | $33.71M | $34.13M | $32.19M | $29.90M |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $322.52M | $234.26M | $326.33M | $371.23M | $151.64M | $207.94M | $232.77M | $191.99M | $215.01M | $168.31M |
| Gross margin | 64.0% | 63.4% | 60.3% | 61.8% | 62.6% | 62.4% | 59.8% | 61.1% | 61.7% | 61.5% |
| Operating margin | 35.0% | 31.8% | 28.9% | 32.1% | 33.6% | 31.7% | 27.4% | 31.2% | 26.3% | 31.0% |
| FCF margin | 26.5% | 20.5% | 29.9% | 33.6% | 13.7% | 20.8% | 24.4% | 19.7% | 21.4% | 17.5% |
| SBC / revenue | 1.3% | 1.4% | 1.5% | 1.3% | 1.3% | 1.5% | 1.5% | 1.6% | 1.6% | 1.5% |
| Current ratio | 1.17x | 1.12x | 1.23x | 1.18x | 1.11x | 1.16x | 1.31x | 1.42x | 1.37x | 1.57x |
| Revenue YoY growth | 9.7% | 14.3% | 14.3% | 13.3% | 10.6% | 3.6% | 5.8% | 6.6% | 6.4% | 7.1% |
| Net margin | 27.8% | Unavailable | 22.8% | 24.8% | 26.5% | Unavailable | 22.7% | 23.9% | Unavailable | Unavailable |
| R&D / revenue | 5.4% | 5.8% | 6.1% | 5.7% | 5.6% | 5.9% | 6.0% | 5.5% | 5.5% | 5.5% |
| CapEx / revenue | 2.0% | 2.8% | 2.7% | 2.8% | 3.1% | 3.0% | 3.1% | 2.9% | 3.3% | 3.1% |
| Long-term debt / equity | 0.19x | Unavailable | 0.23x | 0.24x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 18.9% | 21.7% | 19.2% | 20.4% | 18.9% | 21.7% | 15.7% | 22.1% | 21.5% | 20.3% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IDXX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-20View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-04View SEC filing
10-Q · Filed 2025-05-01View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.